Report: Pfizer, NIH Discussing Study of Longer Paxlovid Dosing Regimen
With increasing concerns about COVID-19 reinfection, Pfizer and the National Institutes of Health are discussing potential studies regarding a longer treatment period with the antiviral medication Paxlovid.